Research & Development
MDIC partners with PerkinElmer's Horizon Discovery on somatic reference samples
The SRSs are expected to be commercially available through Horizon Discovery by early 2024; the characterization data will be available in publicly accessible databases.
October 20, 2022
Guardian Research Network, Northeast Georgia Health partner on clinical research, patient treatment
GRN, whose activities include testing for early cancer diagnosis, said the collaboration aims to enable innovation in clinical research and patient treatment for local, rural, and suburban communities.
September 30, 2022
Group forms to evaluate early cancer detection tests
MCED tests use blood draws, urine, saliva, or stool samples to rapidly screen for multiple types of cancer at once, potentially catching and treating disease earlier. The consortium will evaluate the clinical and public health value of the tests for earlier cancer detection and treatment and establish standards for their use in routine medical care.
April 22, 2021
Study revises thinking on genes and breast cancer risk
The review incorporates the findings of the Cancer Risk Estimates Related to Susceptibility (CARRIERS) consortium, a group evaluating predisposition genes and the incidence of breast cancer. Drawing from U.S. population studies, researchers evaluated hereditary cancer genetic testing for 12 established breast cancer genes in a total of 32,247 women with breast cancer and 32,544 women without breast cancer. Results were published by Fergus Couch, PhD, a consultant in experimental pathology and laboratory medicine at the Mayo Clinic, and colleagues.
January 21, 2021
Neurofilament light blood test shows concussion damage in study of veterans
Sponsored by grant funding from the U.S. Department of Defense (DOD) Chronic Effects of Neurotrauma Consortium (CENC), the study evaluated levels of the protein NfL in blood tests and how they correlated with concussion in 195 military veterans. Researchers found higher levels in veterans with a history of three or more concussions compared to those who had not had mTBI. In addition, high NfL was associated with more severe symptoms such as post-traumatic stress disorder (PTSD) and depression.
May 27, 2020
Real-world study: Genetic testing appears underused in autism
Neurological medicine researchers evaluated how frequently chromosomal microarray (CMA) and fragile X syndrome testing were conducted in people with autism spectrum disorder through the Rhode Island Consortium for Autism Research and Treatment (RI-CART). Results were reported by Dr. Eric Morrow, PhD, head of the Developmental Disorders Genetics Research Program at Brown University, and colleagues in a research letter.
May 13, 2020
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
Dr. Fauci invokes Yogi Berra to describe emerging infectious disease challenge
Thermo Fisher Scientific introduces digital PCR liquid-biopsy assays for academic, clinical research
Thermo Fisher Scientific updates Applied Biosystems genetic analyzers to comply with IVDR
Week in Review: Elizabeth Holmes sentenced; good cholesterol worse for some adults; earlier type 2 diabetes diagnosis; and more
Quest Diagnostics completes acquisition of Summa Health outreach lab services business
Blood biomarkers signal concussion in college athletes
The prospective case-control study was funded by the U.S. Department of Defense and the NCAA and conducted through their Concussion Assessment, Research and Education (CARE) consortium.
February 6, 2020
Fusion Genomics secures $1M U.S. to study respiratory infections panel
The Consortium Québécois sur la Découverte du Medicament (CQDM) is a Montreal-based biomedical research consortium that funds new technologies with potential value in facilitating drug discovery and development. The organization noted that since it was founded in 2008, it has raised more than $118 million Canadian ($90 million U.S.) through Canadian government programs and a wide range of pharmaceutical industry partners, including Merck, Pfizer, AstraZeneca, and Eli Lilly.
January 9, 2020
Are commercial labs falling short in prenatal testing?
NIPS testing involves analyzing blood samples from pregnant women for DNA fragments derived from the placenta. These samples can reveal genetic or chromosomal conditions in a fetus, including Down syndrome, trisomies involving chromosomes 13 or 18, and extra or missing copies of the X or Y sex chromosomes.
April 2, 2019
Page 1 of 1